Aromatic-Cationic Peptides for Mitochondrial Oxidative Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective cure for mitochondrial diseases caused by mutations in the SURF1 or POLG genes, which disrupt mitochondrial oxidative phosphorylation, leading to a range of severe symptoms and conditions.
Innovation Solution
Administering therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or its pharmaceutically acceptable salts, to prevent, treat, or ameliorate the disruption of mitochondrial oxidative phosphorylation associated with these gene mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional palliative treatments (vitamin therapy, energy conservation) are used for mitochondrial diseases, then disease symptoms are temporarily improved, but the underlying mitochondrial dysfunction caused by SURF1 or POLG gene mutations remains uncured
Solution Approach 1:
The patent introduces aromatic-cationic peptides as intermediary molecules that bridge the gap between conventional treatments and the underlying mitochondrial dysfunction. These peptides specifically target and stabilize mitochondrial complexes, acting as a mediator that directly addresses the root cause while maintaining compatibility with existing palliative therapies
Solution Approach 2:
The invention changes the therapeutic parameter from general supportive care to specific molecular intervention. By administering aromatic-cationic peptides that directly interact with mitochondrial protein complexes, the treatment shifts from managing symptoms to correcting the biochemical defects caused by SURF1 or POLG mutations
2Object-affected harmful factors
If no specific treatment is administered for mitochondrial oxidative phosphorylation disruption, then the disease progresses with severe symptoms, but conventional treatments do not address the root cause
Solution Approach 1:
The patent applies preliminary action by administering aromatic-cationic peptides before severe mitochondrial failure occurs. The peptides prevent further disruption of oxidative phosphorylation and stabilize mitochondrial function proactively, rather than reacting to advanced disease states
Solution Approach 2:
The invention converts the harmful effect of mitochondrial instability into a beneficial therapeutic opportunity. The aromatic-cationic peptides exploit the specific structural vulnerabilities caused by SURF1 or POLG mutations to deliver targeted stabilization, turning the disease mechanism itself into a treatment target
Data Source
AI summary
The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.